MedPath

Cefadroxil

Generic Name
Cefadroxil
Drug Type
Small Molecule
Chemical Formula
C16H17N3O5S
CAS Number
50370-12-2
Unique Ingredient Identifier
Q525PA8JJB
Background

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

Indication

For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes

Associated Conditions
Bacterial Infections, Infection and inflammatory reaction due to internal prosthetic device, implant, and graft, Skin and Subcutaneous Tissue Bacterial Infections, Streptococcal Pharyngitis, Tonsillitis streptococcal, Urinary Tract Infection
Clinical Trials
Related News

Or v IV Antibiotics for Infection

Phase 3
Conditions
Joint Infection
Interventions
First Posted Date
2021-01-26
Last Posted Date
2021-01-26
Lead Sponsor
Rothman Institute Orthopaedics
Target Recruit Count
308
Registration Number
NCT04723940
Locations
🇺🇸

Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Phase 4
Conditions
Inflammatory Disease
Tobacco Use
Infections Joint Prosthetic
Overweight or Obesity
Autoimmune Diseases
MSSA Colonization
MRSA
Chronic Kidney Diseases
Diabetes
Interventions
First Posted Date
2020-03-05
Last Posted Date
2024-06-27
Lead Sponsor
Mayo Clinic
Target Recruit Count
4618
Registration Number
NCT04297592
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)

Phase 1
Completed
Conditions
Phenylketonuria
Interventions
Other: Matching Placebo
First Posted Date
2019-09-11
Last Posted Date
2020-09-14
Lead Sponsor
Société des Produits Nestlé (SPN)
Target Recruit Count
18
Registration Number
NCT04085666
Locations
🇩🇪

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

🇦🇺

Linear Clinical Research Ltd, Nedlands, Western Australia, Australia

Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections

Phase 1
Completed
Conditions
Septic Arthritis
Osteomyelitis
Pyomyositis
Interventions
First Posted Date
2019-01-14
Last Posted Date
2021-06-02
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
17
Registration Number
NCT03802552
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Phase 3
Completed
Conditions
Bacterial Infections
Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Skin Infections
Interventions
First Posted Date
2016-06-28
Last Posted Date
2024-01-17
Lead Sponsor
AbbVie
Target Recruit Count
199
Registration Number
NCT02814916
Locations
🇱🇹

Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania

🇧🇬

University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria

🇧🇬

MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria

and more 81 locations

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-06-24
Last Posted Date
2015-06-24
Lead Sponsor
Genuine Research Center, Egypt
Target Recruit Count
24
Registration Number
NCT02479867
Locations
🇪🇬

Genuine Research Center GRC, Cairo, Egypt

A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects

Phase 4
Completed
Conditions
Infections, Urinary Tract
Interventions
First Posted Date
2015-05-18
Last Posted Date
2017-09-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
24
Registration Number
NCT02446496
Locations
🇪🇬

GSK Investigational Site, Cairo, Egypt

Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Phase 2
Completed
Conditions
Pulmonary Tuberculosis
Interventions
Drug: Amoxicillin/clavulanic acid
First Posted Date
2015-03-06
Last Posted Date
2020-03-23
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
58
Registration Number
NCT02381470
Locations
🇵🇭

Tropical Disease Foundation, Makati City, Philippines

🇵🇭

De La Salle Health Institute, Cavite, Philippines

🇸🇬

National University Hospital, Singapore, Singapore, Singapore

and more 3 locations

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

Phase 4
Completed
Conditions
Bacterial Infection
Anti-infective Agents
Breast Implantation
Interventions
First Posted Date
2010-11-19
Last Posted Date
2014-05-13
Lead Sponsor
Stony Brook University
Target Recruit Count
132
Registration Number
NCT01244698
Locations
🇺🇸

Stony Brook University Medical Center, Stony Brook, New York, United States

Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DURICEF® capsules 500 mg
First Posted Date
2009-02-03
Last Posted Date
2024-08-19
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
26
Registration Number
NCT00835081
Locations
🇨🇦

Biovail Contract Research, Toronto, Ontario, Canada

🇺🇸

Bioassay Laboratory, Inc., Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy